Overview
Tangier disease (TD) is named after an island off the coast of Virginia, United States, where it was first identified in a child.1 This child had orange tonsils, abnormally low levels of high-density lipoprotein (HDL), and an enlarged liver and spleen.1 While these symptoms may seem unusual, they can be clearly explained by HDL's vital role in cholesterol transport and removal.
The importance of HDLs
Cholesterol is hydrophobic, meaning it repels or "hates" water, making it unable to mix with or dissolve in water.2 These molecules are essential for maintaining healthy cells as they are key components that provide structure and support to the membranes surrounding the cell itself and organelles such as the nucleus and mitochondria.2
Additionally, they play vital roles in various metabolic processes, including the production of steroid hormones such as oestrogen and testosterone needed for reproduction and bile acids needed for digestion in the gut.2 Since cholesterol is hydrophobic, it is challenging to transport it from the liver, where it is produced, or from the food we consume to our cells. This is because our blood and the cytoplasm of our cells are primarily water.
To transport cholesterol through the body, it is packaged into structures made of fats and proteins, known as lipoproteins.3 This arrangement allows the water-repelling (hydrophobic) cholesterol to be safely enclosed in the centre. At the same time, the water-attracting (hydrophilic) components, including proteins, face outward, allowing the entire structure to move easily through the watery environment of the bloodstream.4
There are several lipoproteins, two of the most well-known being LDLs and HDLs.3 LDLs, or low-density lipoproteins, contain a higher proportion of cholesterol and are responsible for transporting cholesterol from the liver to the cells, which are used for building membranes and other functions.5 In contrast, HDLs, or high-density lipoproteins, have a higher protein content and perform the opposite role.
HDLs collect excess cholesterol from the tissues and bloodstream and transport it back to the liver, where it can be processed and removed from the body.5 This balance between LDL and HDL is essential for maintaining healthy cholesterol levels and reducing the risk of cardiovascular disease.
What is Tangier disease?
Tangier disease is a rare genetic disorder identified in approximately 100 individuals worldwide since its discovery in 1961.6 It is caused by a mutation (a change) in the ATP-binding cassette subfamily A member 1 (ABCA1) gene. Genes act like instruction manuals for our cells, providing the code to produce specific proteins. When a mutation occurs, it can disrupt the structure or function of the resulting protein. In this case, the ABCA1 protein is essential for the production of HDL as it helps transport the cholesterol needed to form HDL particles.7
While some HDL comes from our diet, the majority is produced in the liver. When the ABCA1 transporter is not working properly due to a mutation, HDL production is significantly reduced. As a result, cholesterol cannot be efficiently removed from the body's tissues, leading to its buildup and contributing to the symptoms and complications seen in Tangier disease.6
Importance of diagnosing Tangier disease
As Tangier disease is extremely rare, there is limited data available on the life expectancy of affected individuals.6 However, it is important to understand that Tangier disease can lead to serious complications, such as increasing the risk of cardiovascular disease.6 These complications can impact overall health and quality of life, making early recognition, regular monitoring, and appropriate management essential to help reduce risks and support long-term well-being.6 In this article, we will be exploring the following:
- The key signs and affected organs in Tangier disease
- The progression and severity of the disease
- Considerations of conditions with similar symptoms for differential diagnosis
Key signs and affected organs
Tangier disease affects multiple organ systems due to the buildup of cholesterol in various tissues.6
| Organ | Role in cholesterol processing | Disease mechanism | Symptoms from cholesterol accumulation |
| Liver | The liver is responsible for producing cholesterol, LDLs and HDLs. It also processes excess cholesterol for removal from the body8 | The liver enlarges in Tangier disease because cholesterol cannot be transported adequately out of liver cells. This prevents the normal formation of HDL outside the cells, leading to the buildup and accumulation of cholesterol within the liver, causing it to become swollen and enlarged6 | Enlarged liver6 |
| Spleen | Although not fully understood, the spleen plays a role in lipid metabolism, as its removal has been associated with increased LDL levels9 | Enlarged spleen6 | |
| Lymph node | Excess cholesterol is transported through the lymphatic system to the liver for processing10 | Orange tonsils6 | |
| Nerves | Nerve cells do not have a role in cholesterol processing but they require cholesterol to function normally11 | Both too little and too much cholesterol in nerve cells can be harmful, as an imbalance can disrupt their structure and function, ultimately leading to nerve damage11 | Damage to nerves that extend to our arms, hands, and legs, causing numbness, tingling, weakness, and pain in limbs6 |
| Heart and blood vessels | HDLs and LDLs travel through the blood vessels5 | Damage to the blood vessel walls can lead to the buildup of cholesterol within the vessel lining, increasing the risk of atherosclerosis. Over time, this can cause narrowing or blockage of the arteries, which may result in serious complications such as heart attacks, strokes, or peripheral artery disease, a condition that reduces blood flow to the limbs12 |
Differential diagnosis
It is important to remember that low HDL levels, enlarged liver, and neurological damage are not exclusive to Tangier disease. These clinical features can also occur in a variety of other inherited and acquired conditions. Recognising the broader range of potential causes is essential for accurate diagnosis.
Inherited disorders that may present with similar symptoms include:6
- Abetalipoproteinaemia - Also causes neurological problems
- Niemann-Pick disease - Leads to enlarged liver and spleen, along with neurological deterioration
- Charcot-Marie-Tooth disease - Results in neurological decline
In addition to genetic conditions, certain medications are known to contribute to low HDL levels or neuropathy. These include:6
- Beta-blockers - Can lower HDL levels
- Benzodiazepines - Long-term use may contribute to nerve damage
- Anabolic steroids - Can reduce HDL levels
There are other diseases and conditions that may cause similar clinical features, such as:6
- Human immunodeficiency virus (HIV) - Associated with low HDL levels
- Chronic inflammation - Can contribute to an enlarged liver or spleen
FAQs
Are HDL and LDL good or bad?
HDL is often referred to as ‘good cholesterol,’ while LDL is known as ‘bad cholesterol. ’
Is Tangier disease curable?
There is no current therapy for Tangier disease, but the symptoms can be managed through diet and medications.
At what age does Tangier’s disease start?
Symptoms can present at any point in your life.13
Do low HDL levels make you tired?
There is no direct link between HDL levels and feelings of tiredness. However, research has identified a connection between sleep duration and cholesterol levels. A study suggests that men who sleep for eight hours or more may have a lower risk of elevated LDL levels.14
Summary
Tangier disease is a rare genetic disorder first identified on Tangier Island in Virginia. It is caused by mutations in the ABCA1 gene, leading to extremely low levels of high-density lipoprotein (HDL). This results in tissue cholesterol buildup, causing key symptoms like orange-coloured tonsils, enlarged liver and spleen, swollen lymph nodes, and peripheral neuropathy. Despite low LDL levels, affected individuals may still face early heart disease. It is essential to recognise these distinctive features to diagnose and manage this disease.
Reference
- Information (US), National Center for Biotechnology. ‘Tangier Disease’. Genes and Disease [Internet], National Center for Biotechnology Information (US), 1998. www.ncbi.nlm.nih.gov, https://www.ncbi.nlm.nih.gov/books/NBK22201/.
- Cox, Rafael A., and Mario R. García-Palmieri. ‘Cholesterol, Triglycerides, and Associated Lipoproteins’. Clinical Methods: The History, Physical, and Laboratory Examinations, edited by H. Kenneth Walker et al., 3rd ed., Butterworths, 1990. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK351/.
- Lent-Schochet, Daniella, and Ishwarlal Jialal. ‘Biochemistry, Lipoprotein Metabolism’. StatPearls, StatPearls Publishing, 2025. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK553193/.
- Feingold, Kenneth R. ‘Introduction to Lipids and Lipoproteins’. Endotext, edited by Kenneth R. Feingold et al., MDText.com, Inc., 2000. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK305896/.
- Huff, Trevor, et al. ‘Physiology, Cholesterol’. StatPearls, StatPearls Publishing, 2025. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK470561/.
- Alshaikhli, Alfarooq, and Sarosh Vaqar. ‘Tangier Disease’. StatPearls, StatPearls Publishing, 2025. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK562250/.
- Wang, Nan, and Marit Westerterp. ‘ABC Transporters, Cholesterol Efflux, and Implications for Cardiovascular Diseases’. Advances in Experimental Medicine and Biology, vol. 1276, 2020, pp. 67–83. PubMed, https://doi.org/10.1007/978-981-15-6082-8_6.
- Kalra, Arjun, et al. ‘Physiology, Liver’. StatPearls, StatPearls Publishing, 2025. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK535438/.
- Gunes, Orgun, et al. ‘The Impact of Splenectomy on Human Lipid Metabolism’. Upsala Journal of Medical Sciences, vol. 127, June 2022, p. 10.48101/ujms.v127.8500. PubMed Central, https://doi.org/10.48101/ujms.v127.8500.
- Huang, Li-Hao, et al. ‘The Role of the Lymphatic System in Cholesterol Transport’. Frontiers in Pharmacology, vol. 6, Sept. 2015, p. 182. PubMed Central, https://doi.org/10.3389/fphar.2015.00182.
- Orth, Matthias, and Stefano Bellosta. ‘Cholesterol: Its Regulation and Role in Central Nervous System Disorders’. Cholesterol, vol. 2012, 2012, p. 292598. PubMed Central, https://doi.org/10.1155/2012/292598.
- Bailey, Adrian, and Shamim S. Mohiuddin. ‘Biochemistry, High Density Lipoprotein’. StatPearls, StatPearls Publishing, 2025. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK549802/.
- Hammans, Simon R. ‘Chapter 11 - Neuropathies’. Practical Guide to Neurogenetics, edited by Thomas T. Warner and Simon R. Hammans, W.B. Saunders, 2009, pp. 175–96. ScienceDirect, https://doi.org/10.1016/B978-0-7506-5410-4.00011-6.
- Kaneita, Yoshitaka, et al. ‘Associations of Usual Sleep Duration with Serum Lipid and Lipoprotein Levels’. Sleep, vol. 31, no. 5, May 2008, pp. 645–52. PubMed Central, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2398756/.

